[It is unclear whether pelvic lymphadenectomy is of oncological benefit in prostate cancer].

Fossati’s 2017 review questions the value of pelvic lymphadenectomy (pLA) in radical prostatectomy (RP) because available studies fail to show any oncological benefit. Our finding that no spread of metastatic lymph nodes (LN) has been demonstrated is based on registry data, clinical trials without evidence of pLA benefit and considerations of the genetic link between […]

[Current practice patterns of perioperative cystectomy management in Germany: a questionnaire survey].

 Radical cystectomy (RCX) is the standard treatment for muscle-invasive and treatment-refractory non-invasive bladder cancer, but that is associated with high morbidity. We now survey current practice patterns on perioperative management among German urological departments of all sizes METHODS:  Members of the German Association of Urology and the German Society of Residents in Urology (GeSRU) were […]

Radical cystectomy: the importance of oncological concepts rather than surgical technique/RC for MIBC — Rafael Sanchez-Salas

Ashish M. Kamat: Welcome everybody to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat from MD Anderson Cancer Center in Houston, and it’s our pleasure and privilege today to welcome Dr. Rafael Sanchez Salas from the Montsouris Institute in France. Dr. Sanchez Salas is a well-known entity in the urologic oncology field. And today he […]

Growing Old with an Overactive Bladder

I recently saw a 77 year-old Latina woman with complaints of strong urinary urgency resulting in incontinence, frequency every 2 hours with nocturia x4.  She described urgency as “pressure in my bladder.” She reported that her symptoms were “terrible.” Her symptoms were longstanding but appeared to be worsening. She had undergone lumbar spinal fusion 18 […]

NIH Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins, Adaptive COVID-19 Treatment Trial 3 (ACTT 3)

San Francisco, CA (UroToday.com) A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in patients with coronavirus disease 2019 (COVID-19) has begun. The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized […]

X